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Abstract Over the last 10 years substantial progress has been
made in our understanding of the genetic basis for type 2
diabetes and related traits. These developments have been
facilitated by technological advancements that have allowed
comprehensive genome-wide assessments of the impact of
common genetic variation on disease risk. Current efforts are
now focused on extending this to genetic variants in the rare
and low-frequency spectrum by capitalising on next-
generation sequencing technologies. This review discusses
the important contributions that studies in isolated populations
are making to this effort for diabetes and metabolic disease,
drawing on specific examples from populations in Greece and
Greenland. This review summarises a presentation given at
the ‘Exciting news in genetics of diabetes’ symposium at the
2015 annual meeting of the EASD, with topics presented by
Eleftheria Zeggini and Torben Hansen, and an overview by
the Session Chair, Anna Gloyn.
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The search for low-frequency and rare variants associated
with complex traits requires very large sample sizes to attain
the necessary power to detect these effects. Population isolates
offer the opportunity to discover such signals withmuch lower
sample sizes. Isolated, or founder, populations have typically
gone through a bottleneck event, followed by population ex-
pansion with limited rates of migration. These characteristics
can offer power advantages in the study of complex trait ge-
netics, especially with respect to the identification of associa-
tion signals at low frequency, and rare variants that would
otherwise be difficult or impossible to detect in cosmopolitan
populations [1, 2]. Some rare variation present in the source
population may have been lost in the isolated population, and
this can reduce the number of neutral rare variants, which in
turn can increase the power of burden tests (i.e. association
tests looking for an aggregation of multiple rare variants in a
functional unit, e.g. gene or regulatory region). Other rare
variants that have made it through the bottleneck can increase
in frequency due to drift, or in some cases, selection. This in
turn increases the power of association studies as smaller sam-
ple sizes are required to detect individual risk loci for complex
diseases and traits. In addition, the genomes of isolates have
been shaped by population history to typically have longer
stretches of linkage disequilibrium. Founder populations also
tend to have more homogeneous environmental exposures
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and, in some cases, deep information on genealogy. These
attributes can be further enhanced through the ability to recall
participants for further characterisation based on genotype and
through access to their medical records. Over the last few
years, the field of complex trait genetics has witnessed a
flourishing of genetic association studies focusing on isolated
populations, with the majority of findings replicating across
cosmopolitan populations [3–12]. Here, we outline examples
from two founder populations stemming from geographical
coordinates in Europe ranging from the extreme North and
South: Greek individuals from the island of Crete in the south
Mediterranean and Inuit individuals from the island of
Greenland in the Arctic (Fig. 1).
The inhabitants of the island of Crete in Greece have in the
past been investigated through epidemiological studies focus-
ing on dietary and nutrition patterns with respect to metabolic
disease [13, 14]. The Hellenic Isolated Cohorts (HELIC)
Minoan Isolates (MANOLIS) study was launched in 2008
with the explicit aim of studying the genetic basis of metabol-
ically relevant complex traits in the isolated population resid-
ing in the villages of the mountainous Mylopotamos region of
Crete (www.helic.org). Anecdotally, this population is known
to enjoy good health in old age despite a diet high in animal
fat. A total of 1600 recontactable individuals (making up
>10% of the total population) were recruited into the study
and subjected to extensive phenotyping, including
anthropometry, detailed diet and lifestyle information,
medical history, and blood sample collection for DNA
extraction as well as biochemical, haematological and other
biomarker analyses. Following genome-wide genotyping and
low-depth whole genome sequencing of the entire cohort, as-
sociation analysis was carried out for quantitative traits of
metabolic relevance measured in the population (such as
fasting glucose and insulin levels, lipid traits and
anthropometry).
Initial population genetic analyses revealed statistically sig-
nificant enrichment of missense (and therefore potentially
functional coding) variants that have substantially risen in
frequency in the isolate compared with the general Greek
population [15]. A genome-wide scan for association with
lipid traits identified a cardioprotective effect at a nonsense
variant, p.Arg19Ter, in the APOC3 gene. The variant abro-
gates expression of all three isoforms of the gene and has a
























































Fig. 1 Allele frequencies (displayed on log scale) of isolate-enriched
variants in Greenland, Crete and the UK general population (UK10K
frequencies are taken fromwww.uk10k.org [21]). Frequency bars are
pink for APOC3 p.Arg19Ter (rs76353203) [11], blue for TBC1D4
p.Arg684Ter (rs61736969) [7] and green for FADS2 rs7477191 [18].
The larger graphs show box plots of blood triglyceride levels by
APOC3 p.Arg19Ter genotype in Crete, and plasma glucose levels by
TBC1D4 p.Arg684Ter in Greenland
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source population (Fig. 1) [11]. The same variant had previ-
ously been found to have risen to similar frequency and to
have a similar protective association with lipid levels in the
Old Order Amish, an independent founder population [8].
Haplotype analysis demonstrated that the variant predates
the divergence of both isolates from the general European
population. Interestingly, the Amish also have a diet high in
animal fat, indicating that the variant may have risen in fre-
quency because of its cardioprotective effect; however, further
analyses were not powered to detect selection signatures due
to the low allele frequency (~2%) [11]. No homozygous indi-
viduals were observed in either founder population. Recent
work has shown that oligonucleotide-mediated inhibition of
APOC3 has therapeutic potential as it decreases blood triacyl-
glycerol (triglyceride) levels [16]. Further recent studies have
also identified associations between a burden of multiple
loss-of-function (LoF) variants in the APOC3 gene and lipid
levels in the general European population [5, 17]. This story
represents a proof-of-principle for the power of isolated pop-
ulations in medically relevant trait locus discovery, exempli-
fied by an early finding with significant translational potential
that is transferable to cosmopolitan populations.
The Greenlandic population is a historically small and iso-
lated founder population. It stands out in at least one important
way in comparison with other well-studied founder popula-
tions, such as the Finnish and Icelandic populations: these
other founder populations are all genetically similar to at least
one large population, whereas the Greenlandic Inuit are not
closely related to any large population [18]. The Greenlandic
Inuit and indigenous populations throughout the Arctic have
different fat distribution compared with Europeans [19].
Furthermore, the isolated Greenlandic Inuit population has
lower levels of plasma glucose and serum insulin and higher
levels of HDL cholesterol than Danes at any given level of
obesity [19]. Little is known about how genetics and lifestyle
behaviour, particularly physical activity, interact to influence
metabolic health in Inuit and whether a recent risk increase of
developing type 2 diabetes and related cardiometabolic con-
ditions is driven by a transition from a traditional subsistence
lifestyle to a modern, industrialised way of life.
A common Greenlandic Inuit-specific nonsense
p.Arg684Ter variant (in which arginine is replaced by a ter-
mination codon) in the gene TBC1D4, with an allele frequen-
cy of 17%, was recently discovered (Fig. 1). It was shown that
homozygous carriers of this variant have markedly elevated
2 h serum insulin levels, postprandial hyperglycaemia, im-
paired glucose tolerance and a tenfold increased risk of type
2 diabetes [7]. The variant explains about 15% of type 2 dia-
betes occurrence in Greenland. Analyses of skeletal muscle
biopsies in groups of three individuals carrying zero, one or
two copies of p.Arg684Ter revealed that hetero- and homozy-
gous carriers of this stop-gained variant in the gene coding for
TBC1D4 are characterised by a marked decrease in the RNA
and protein expression of the skeletal muscle-specific long
isoform of TBC1D4. Other tissues such as pancreatic beta
cells, adipose tissue and liver tissue expressing the short iso-
form of TBC1D4 were not affected by the stop-gained muta-
tion [7]. Thus, homozygous carriers of p.Arg684Ter could be
considered as human muscle-specific knockouts of TBC1D4.
Since the variant is common in Greenland (allele frequency of
17%) and rare/absent in all other populations, it is possible that
selection has historically favoured it in Inuit, possibly because
of the low carbohydrate diet associated with traditional Inuit
lifestyle. Indeed, weak evidence for positive selection was
found [7]. The finding of a common tissue-specific and
Inuit-specific LoF variant constitutes proof-of-concept that
conducting genetic association studies in small and isolated
populations can reveal population-specific type 2 diabetes risk
variants and novel biological insights.
While other LoF variants in Inuit may have increased in
frequency by chance (genetic drift), it is conceivable that some
variants are common specifically in Inuit because of adapta-
tion to the special climate and environment in the Arctic. In
fact, a recent study of signs of selection identified genetic
variants in fat metabolism in the region of the FADS1-3 genes
that alter metabolism of the large amounts of polyunsaturated
fatty acids found in the traditional Inuit seafood diet. Gene
variants under selection have a strong effect on height and
weight, of up to 2 cm and 4 kg, respectively, as well as a
protective effect on cholesterol and triacylglycerol levels
[20]. This study illustrates the utility of evolutionary studies
of locally adapted populations for understanding the genetic
basis of phenotypic variation among humans.
What is becoming increasingly clear is that rare variants of
large effect are most likely to be specific to or enriched in
particular ancestries. These illustrations from Greece and
Greenland provide elegant examples of the opportunities for
translational biology offered through the discovery of rare
coding alleles that alter disease risk. Detailed physiological
studies in carriers of these alleles offer the potential to under-
stand the impact of perturbing particular biological pathways
in humans, offering the chance to understand the interplay of
proteins in multiple regulatory pathways shedding light on
likely adverse on-target effects of therapeutic manipulation.
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